Humacyte Announces Publication Highlighting the First Use of the Human Acellular Vessel (HAV™) as Arterial Bypass Conduit for Replacement of Infected Prosthetic Graft
December 15, 2021 07:30 ET
|
Humacyte, Inc
-- Vanderbilt University Medical Center patient received the HAV under the U.S. Food and Drug Administration’s (FDA) Expanded Access Program (EAP) in April 2019 -- -- After replacement, the patient...
Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021
November 16, 2021 07:30 ET
|
Humacyte, Inc
-- Patency and host cell remodeling of the HAV were observed in all study implants – -- Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac...
Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System
November 15, 2021 09:30 ET
|
Humacyte, Inc
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at...
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 12, 2021 07:30 ET
|
Humacyte, Inc
-- Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds -- -- Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel...
Humacyte Leadership to Present at Credit Suisse 30th Annual Healthcare Conference
November 09, 2021 07:30 ET
|
Humacyte, Inc
DURHAM, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Leadership to Present at Multiple Scientific Events in November
November 08, 2021 07:30 ET
|
Humacyte, Inc
DURHAM, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Leadership to Present at Seven Scientific and Industry Events in October
October 05, 2021 07:30 ET
|
Humacyte, Inc
DURHAM, N.C., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengineered Human Tissue Platform
September 20, 2021 08:45 ET
|
Humacyte, Inc
Patent estate also expanded by the issuance of 23 additional patents in international marketsHumacyte now owns or licenses 119 patents covering its proprietary platform DURHAM, N.C., Sept. 20,...
Humacyte Leadership to Present at Five Scientific Events in September
September 17, 2021 07:51 ET
|
Humacyte, Inc
DURHAM, N.C., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...